Ana Gleisner
Concepts (345)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatectomy | 60 | 2026 | 256 | 8.700 |
Why?
| | Liver Neoplasms | 54 | 2026 | 776 | 6.900 |
Why?
| | Carcinoma, Hepatocellular | 38 | 2026 | 370 | 6.270 |
Why?
| | Cholangiocarcinoma | 20 | 2026 | 110 | 3.830 |
Why?
| | Pancreatic Neoplasms | 25 | 2025 | 944 | 3.790 |
Why?
| | Bile Duct Neoplasms | 19 | 2026 | 132 | 3.520 |
Why?
| | Adenocarcinoma | 25 | 2024 | 927 | 3.280 |
Why?
| | Laparoscopy | 10 | 2026 | 487 | 2.980 |
Why?
| | Neoplasm Recurrence, Local | 26 | 2026 | 1160 | 2.720 |
Why?
| | Sentinel Lymph Node | 8 | 2022 | 49 | 2.610 |
Why?
| | Minimally Invasive Surgical Procedures | 8 | 2026 | 196 | 2.390 |
Why?
| | Melanoma | 12 | 2022 | 765 | 2.350 |
Why?
| | Sentinel Lymph Node Biopsy | 12 | 2025 | 118 | 2.280 |
Why?
| | Skin Neoplasms | 12 | 2022 | 806 | 2.270 |
Why?
| | Lymph Node Excision | 13 | 2026 | 174 | 2.180 |
Why?
| | Pancreaticoduodenectomy | 11 | 2024 | 149 | 2.100 |
Why?
| | Postoperative Complications | 27 | 2026 | 3034 | 2.010 |
Why?
| | Tumor Burden | 18 | 2026 | 326 | 1.910 |
Why?
| | Pancreatectomy | 8 | 2025 | 289 | 1.710 |
Why?
| | Survival Rate | 41 | 2026 | 2092 | 1.500 |
Why?
| | Robotic Surgical Procedures | 4 | 2026 | 210 | 1.470 |
Why?
| | Retrospective Studies | 98 | 2026 | 17438 | 1.460 |
Why?
| | Bilirubin | 7 | 2026 | 101 | 1.350 |
Why?
| | Prognosis | 49 | 2026 | 4351 | 1.330 |
Why?
| | Aged | 99 | 2026 | 26432 | 1.300 |
Why?
| | Lymph Nodes | 10 | 2026 | 511 | 1.260 |
Why?
| | Colorectal Neoplasms | 10 | 2026 | 874 | 1.210 |
Why?
| | Middle Aged | 107 | 2026 | 36619 | 1.100 |
Why?
| | Databases, Factual | 20 | 2025 | 1493 | 1.090 |
Why?
| | Breast Neoplasms | 6 | 2025 | 2418 | 1.080 |
Why?
| | Lymphatic Metastasis | 17 | 2026 | 335 | 1.030 |
Why?
| | Liver Transplantation | 12 | 2025 | 751 | 0.970 |
Why?
| | Esophageal Neoplasms | 8 | 2025 | 351 | 0.920 |
Why?
| | Risk Assessment | 23 | 2026 | 3712 | 0.870 |
Why?
| | Female | 119 | 2026 | 79499 | 0.850 |
Why?
| | Esophagectomy | 4 | 2021 | 136 | 0.850 |
Why?
| | Humans | 150 | 2026 | 146342 | 0.840 |
Why?
| | Male | 114 | 2026 | 73396 | 0.810 |
Why?
| | Serum Albumin | 6 | 2025 | 147 | 0.780 |
Why?
| | Conversion to Open Surgery | 2 | 2020 | 22 | 0.760 |
Why?
| | Thrombelastography | 1 | 2024 | 182 | 0.760 |
Why?
| | Neoplasm Staging | 14 | 2026 | 1488 | 0.750 |
Why?
| | alpha-Fetoproteins | 5 | 2025 | 42 | 0.750 |
Why?
| | Nomograms | 2 | 2022 | 59 | 0.740 |
Why?
| | Follow-Up Studies | 26 | 2026 | 5439 | 0.710 |
Why?
| | Carcinoma, Pancreatic Ductal | 5 | 2023 | 297 | 0.680 |
Why?
| | Rectal Neoplasms | 5 | 2023 | 160 | 0.660 |
Why?
| | Machine Learning | 4 | 2026 | 594 | 0.570 |
Why?
| | Colonic Neoplasms | 3 | 2024 | 259 | 0.560 |
Why?
| | Treatment Outcome | 30 | 2026 | 11821 | 0.530 |
Why?
| | Head and Neck Neoplasms | 6 | 2019 | 563 | 0.500 |
Why?
| | Quality of Life | 2 | 2019 | 3200 | 0.490 |
Why?
| | Metastasectomy | 3 | 2024 | 19 | 0.490 |
Why?
| | CA-19-9 Antigen | 3 | 2026 | 36 | 0.480 |
Why?
| | Predictive Value of Tests | 10 | 2026 | 2113 | 0.470 |
Why?
| | Peritoneal Neoplasms | 3 | 2024 | 103 | 0.460 |
Why?
| | Neoadjuvant Therapy | 11 | 2023 | 475 | 0.450 |
Why?
| | Hepatic Artery | 2 | 2026 | 53 | 0.450 |
Why?
| | Colectomy | 3 | 2013 | 119 | 0.450 |
Why?
| | Aged, 80 and over | 20 | 2025 | 8391 | 0.430 |
Why?
| | Liver Failure | 3 | 2009 | 79 | 0.420 |
Why?
| | Risk Factors | 21 | 2026 | 10921 | 0.390 |
Why?
| | Disease-Free Survival | 11 | 2025 | 778 | 0.390 |
Why?
| | Axilla | 3 | 2023 | 51 | 0.390 |
Why?
| | Length of Stay | 8 | 2026 | 1358 | 0.380 |
Why?
| | Stomach Neoplasms | 2 | 2024 | 128 | 0.370 |
Why?
| | Cytoreduction Surgical Procedures | 3 | 2024 | 69 | 0.360 |
Why?
| | Blood Loss, Surgical | 4 | 2026 | 117 | 0.360 |
Why?
| | Decision Making | 1 | 2019 | 993 | 0.350 |
Why?
| | Propensity Score | 4 | 2024 | 376 | 0.340 |
Why?
| | Ampulla of Vater | 2 | 2024 | 40 | 0.330 |
Why?
| | Margins of Excision | 5 | 2025 | 55 | 0.320 |
Why?
| | Decision Support Techniques | 2 | 2025 | 478 | 0.310 |
Why?
| | ROC Curve | 5 | 2025 | 617 | 0.300 |
Why?
| | Adult | 39 | 2026 | 41087 | 0.300 |
Why?
| | United States | 19 | 2025 | 16136 | 0.300 |
Why?
| | Liver Cirrhosis | 5 | 2025 | 278 | 0.290 |
Why?
| | Benchmarking | 2 | 2021 | 193 | 0.290 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 2 | 2019 | 15 | 0.290 |
Why?
| | Serum Albumin, Human | 2 | 2025 | 7 | 0.290 |
Why?
| | Preoperative Care | 5 | 2025 | 396 | 0.280 |
Why?
| | Neuroendocrine Tumors | 2 | 2023 | 122 | 0.280 |
Why?
| | Gallbladder Neoplasms | 2 | 2024 | 20 | 0.270 |
Why?
| | Time Factors | 10 | 2025 | 7109 | 0.260 |
Why?
| | Quality Indicators, Health Care | 3 | 2026 | 343 | 0.250 |
Why?
| | Mastectomy, Segmental | 2 | 2017 | 107 | 0.250 |
Why?
| | Lymphocytes | 2 | 2025 | 379 | 0.240 |
Why?
| | Proportional Hazards Models | 5 | 2025 | 1331 | 0.240 |
Why?
| | Inflammation | 4 | 2025 | 2919 | 0.240 |
Why?
| | Aspartate Aminotransferases | 1 | 2026 | 86 | 0.230 |
Why?
| | Survival Analysis | 7 | 2024 | 1378 | 0.230 |
Why?
| | Vena Cava, Inferior | 1 | 2026 | 80 | 0.230 |
Why?
| | Catheter Ablation | 2 | 2008 | 355 | 0.220 |
Why?
| | Abdominal Neoplasms | 1 | 2025 | 48 | 0.220 |
Why?
| | Time-to-Treatment | 2 | 2025 | 257 | 0.220 |
Why?
| | Infusions, Intra-Arterial | 1 | 2025 | 61 | 0.220 |
Why?
| | gamma-Glutamyltransferase | 1 | 2025 | 42 | 0.220 |
Why?
| | Hyperglycemia | 2 | 2020 | 384 | 0.220 |
Why?
| | Neoplasm Invasiveness | 6 | 2026 | 504 | 0.220 |
Why?
| | Medical Futility | 1 | 2025 | 32 | 0.210 |
Why?
| | Anastomotic Leak | 1 | 2024 | 46 | 0.210 |
Why?
| | Portal Vein | 1 | 2026 | 123 | 0.210 |
Why?
| | Abdomen, Acute | 1 | 2004 | 20 | 0.210 |
Why?
| | Age Factors | 5 | 2025 | 3347 | 0.210 |
Why?
| | End Stage Liver Disease | 1 | 2025 | 84 | 0.200 |
Why?
| | Cohort Studies | 10 | 2023 | 6077 | 0.200 |
Why?
| | Bacterial Infections | 3 | 2006 | 247 | 0.200 |
Why?
| | Lymphopenia | 1 | 2024 | 62 | 0.200 |
Why?
| | Biomarkers, Tumor | 3 | 2025 | 1339 | 0.200 |
Why?
| | Chemotherapy, Adjuvant | 6 | 2025 | 429 | 0.200 |
Why?
| | Odds Ratio | 4 | 2019 | 1077 | 0.190 |
Why?
| | Combined Modality Therapy | 6 | 2024 | 1271 | 0.190 |
Why?
| | Operative Time | 4 | 2026 | 195 | 0.190 |
Why?
| | Cannabinoids | 1 | 2025 | 182 | 0.190 |
Why?
| | Kaplan-Meier Estimate | 4 | 2025 | 970 | 0.190 |
Why?
| | Practice Guidelines as Topic | 2 | 2024 | 1591 | 0.190 |
Why?
| | Multilocus Sequence Typing | 1 | 2022 | 16 | 0.190 |
Why?
| | SEER Program | 2 | 2014 | 233 | 0.190 |
Why?
| | C-Reactive Protein | 1 | 2025 | 429 | 0.190 |
Why?
| | Lymphoscintigraphy | 2 | 2019 | 10 | 0.190 |
Why?
| | Sunburn | 1 | 2002 | 26 | 0.180 |
Why?
| | Surgical Oncology | 1 | 2022 | 30 | 0.180 |
Why?
| | Sunscreening Agents | 1 | 2002 | 25 | 0.180 |
Why?
| | Nevus, Pigmented | 1 | 2002 | 35 | 0.180 |
Why?
| | Patient Selection | 2 | 2025 | 728 | 0.180 |
Why?
| | Pelvic Exenteration | 2 | 2019 | 12 | 0.180 |
Why?
| | Lung Neoplasms | 3 | 2023 | 2675 | 0.180 |
Why?
| | Prospective Studies | 9 | 2025 | 8123 | 0.180 |
Why?
| | Killer Cells, Natural | 1 | 2025 | 481 | 0.170 |
Why?
| | Klatskin Tumor | 1 | 2021 | 18 | 0.170 |
Why?
| | Mastectomy | 1 | 2023 | 189 | 0.170 |
Why?
| | Platelet Count | 3 | 2026 | 95 | 0.170 |
Why?
| | Anesthetics, Inhalation | 1 | 2021 | 52 | 0.160 |
Why?
| | Chemoradiotherapy | 4 | 2023 | 238 | 0.160 |
Why?
| | Body Mass Index | 3 | 2025 | 2458 | 0.160 |
Why?
| | Hyperthermia, Induced | 2 | 2020 | 119 | 0.160 |
Why?
| | Propofol | 1 | 2021 | 86 | 0.160 |
Why?
| | Organ Preservation | 4 | 2023 | 123 | 0.150 |
Why?
| | Cancer Survivors | 1 | 2025 | 348 | 0.150 |
Why?
| | Scalp | 1 | 2019 | 38 | 0.150 |
Why?
| | Regression Analysis | 2 | 2019 | 999 | 0.150 |
Why?
| | Artificial Intelligence | 1 | 2024 | 389 | 0.140 |
Why?
| | Pancreatic Diseases | 1 | 2019 | 64 | 0.140 |
Why?
| | Reoperation | 3 | 2017 | 645 | 0.140 |
Why?
| | Registries | 2 | 2021 | 2400 | 0.140 |
Why?
| | Skin Pigmentation | 1 | 2019 | 44 | 0.140 |
Why?
| | Neutrophils | 1 | 2024 | 1133 | 0.140 |
Why?
| | Phenotype | 2 | 2026 | 3206 | 0.130 |
Why?
| | Appendiceal Neoplasms | 1 | 2017 | 28 | 0.130 |
Why?
| | Referral and Consultation | 1 | 2024 | 881 | 0.130 |
Why?
| | Population Surveillance | 1 | 2021 | 481 | 0.130 |
Why?
| | Tomography, X-Ray Computed | 3 | 2025 | 2786 | 0.130 |
Why?
| | Anesthesia | 1 | 2021 | 257 | 0.130 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2017 | 28 | 0.130 |
Why?
| | Patient Acceptance of Health Care | 1 | 2024 | 881 | 0.130 |
Why?
| | Patient Compliance | 1 | 2021 | 589 | 0.130 |
Why?
| | Pylorus | 1 | 2017 | 17 | 0.120 |
Why?
| | Gastric Outlet Obstruction | 1 | 2017 | 12 | 0.120 |
Why?
| | Waiting Lists | 2 | 2009 | 251 | 0.120 |
Why?
| | Carcinoma, Renal Cell | 2 | 2026 | 231 | 0.120 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2017 | 92 | 0.120 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 143 | 0.120 |
Why?
| | Disease Management | 1 | 2021 | 651 | 0.120 |
Why?
| | Analgesics, Opioid | 1 | 2025 | 1221 | 0.120 |
Why?
| | Hospitals, High-Volume | 1 | 2016 | 51 | 0.120 |
Why?
| | Nutritional Status | 1 | 2019 | 346 | 0.120 |
Why?
| | Cancer Care Facilities | 1 | 2016 | 48 | 0.120 |
Why?
| | Neoplasms | 2 | 2022 | 2954 | 0.120 |
Why?
| | Neuromuscular Agents | 1 | 2017 | 46 | 0.120 |
Why?
| | Hospitals | 1 | 2021 | 738 | 0.120 |
Why?
| | Genital Neoplasms, Female | 1 | 2017 | 100 | 0.120 |
Why?
| | Botulinum Toxins, Type A | 1 | 2017 | 60 | 0.120 |
Why?
| | Obesity | 2 | 2025 | 3131 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 1998 | 0.110 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2016 | 104 | 0.110 |
Why?
| | Cannabis | 1 | 2023 | 521 | 0.110 |
Why?
| | Adenoma | 1 | 2017 | 210 | 0.110 |
Why?
| | Patient Reported Outcome Measures | 1 | 2019 | 516 | 0.110 |
Why?
| | Kidney Neoplasms | 2 | 2026 | 419 | 0.110 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 1195 | 0.100 |
Why?
| | Delivery of Health Care | 1 | 2021 | 947 | 0.100 |
Why?
| | Radiosurgery | 1 | 2018 | 398 | 0.100 |
Why?
| | Morbidity | 4 | 2021 | 319 | 0.100 |
Why?
| | Patient Readmission | 1 | 2019 | 778 | 0.100 |
Why?
| | Antineoplastic Agents | 3 | 2021 | 2219 | 0.100 |
Why?
| | Unnecessary Procedures | 1 | 2014 | 56 | 0.100 |
Why?
| | Trauma Centers | 2 | 2014 | 441 | 0.100 |
Why?
| | Hospital Mortality | 4 | 2024 | 1051 | 0.100 |
Why?
| | Anti-Bacterial Agents | 1 | 2004 | 1942 | 0.100 |
Why?
| | Abdomen | 1 | 2013 | 142 | 0.090 |
Why?
| | Radiation Dosage | 1 | 2014 | 193 | 0.090 |
Why?
| | Preoperative Period | 2 | 2025 | 157 | 0.090 |
Why?
| | Renal Insufficiency | 1 | 2013 | 173 | 0.080 |
Why?
| | Pandemics | 3 | 2025 | 1707 | 0.080 |
Why?
| | Severity of Illness Index | 3 | 2025 | 2921 | 0.080 |
Why?
| | Clinical Competence | 1 | 2019 | 1272 | 0.080 |
Why?
| | Asia | 2 | 2021 | 69 | 0.080 |
Why?
| | Triage | 1 | 2012 | 243 | 0.080 |
Why?
| | Logistic Models | 2 | 2025 | 2126 | 0.070 |
Why?
| | Europe | 2 | 2021 | 421 | 0.070 |
Why?
| | Organ Preservation Solutions | 2 | 2006 | 47 | 0.070 |
Why?
| | Graft Survival | 2 | 2009 | 523 | 0.070 |
Why?
| | Kidney Transplantation | 2 | 2013 | 735 | 0.070 |
Why?
| | Diagnostic Tests, Routine | 2 | 2024 | 109 | 0.070 |
Why?
| | Brain Injuries | 1 | 2014 | 499 | 0.070 |
Why?
| | Bile Ducts, Extrahepatic | 1 | 2008 | 19 | 0.070 |
Why?
| | Laparotomy | 1 | 2008 | 111 | 0.070 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1408 | 0.070 |
Why?
| | Biliary Tract Surgical Procedures | 1 | 2008 | 26 | 0.070 |
Why?
| | Case-Control Studies | 2 | 2007 | 3647 | 0.060 |
Why?
| | Cholangitis, Sclerosing | 1 | 2008 | 56 | 0.060 |
Why?
| | Electrocoagulation | 1 | 2007 | 35 | 0.060 |
Why?
| | Anus Neoplasms | 1 | 2007 | 33 | 0.060 |
Why?
| | Intraoperative Care | 1 | 2007 | 68 | 0.060 |
Why?
| | Congenital Hypothyroidism | 1 | 1986 | 10 | 0.060 |
Why?
| | Brazil | 2 | 2008 | 179 | 0.060 |
Why?
| | Multivariate Analysis | 2 | 2025 | 1543 | 0.060 |
Why?
| | Young Adult | 7 | 2022 | 14330 | 0.060 |
Why?
| | Guideline Adherence | 2 | 2024 | 594 | 0.060 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2026 | 28 | 0.060 |
Why?
| | Vascular Patency | 1 | 2026 | 115 | 0.060 |
Why?
| | Fluorouracil | 2 | 2022 | 231 | 0.060 |
Why?
| | Ultrasonography, Interventional | 1 | 2007 | 163 | 0.060 |
Why?
| | Mycophenolic Acid | 1 | 2006 | 117 | 0.060 |
Why?
| | Chemotherapy, Cancer, Regional Perfusion | 1 | 2024 | 30 | 0.050 |
Why?
| | Sample Size | 1 | 2025 | 124 | 0.050 |
Why?
| | Lymphocyte Count | 1 | 2024 | 167 | 0.050 |
Why?
| | Adolescent | 9 | 2022 | 22557 | 0.050 |
Why?
| | Wounds and Injuries | 1 | 2012 | 959 | 0.050 |
Why?
| | Zygomycosis | 1 | 2003 | 6 | 0.050 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2019 | 222 | 0.050 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2024 | 62 | 0.050 |
Why?
| | Developmental Disabilities | 1 | 1986 | 281 | 0.050 |
Why?
| | Sarcoma | 1 | 2026 | 209 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2026 | 5899 | 0.050 |
Why?
| | Cluster Analysis | 1 | 2025 | 496 | 0.050 |
Why?
| | Comorbidity | 2 | 2022 | 1665 | 0.050 |
Why?
| | Hepatocytes | 1 | 2004 | 224 | 0.050 |
Why?
| | Antibiotic Prophylaxis | 1 | 2004 | 140 | 0.050 |
Why?
| | Gastrectomy | 1 | 2024 | 164 | 0.050 |
Why?
| | Biology | 1 | 2023 | 90 | 0.050 |
Why?
| | Capecitabine | 1 | 2022 | 56 | 0.040 |
Why?
| | Appendicitis | 1 | 2004 | 151 | 0.040 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2007 | 628 | 0.040 |
Why?
| | Pneumonectomy | 1 | 2023 | 169 | 0.040 |
Why?
| | Anesthesia, Intravenous | 1 | 2021 | 23 | 0.040 |
Why?
| | Anesthetics, Intravenous | 1 | 2021 | 67 | 0.040 |
Why?
| | Esophagogastric Junction | 1 | 2021 | 54 | 0.040 |
Why?
| | Models, Biological | 1 | 2008 | 1761 | 0.040 |
Why?
| | Induction Chemotherapy | 1 | 2021 | 87 | 0.040 |
Why?
| | Surgical Wound Infection | 1 | 2004 | 349 | 0.040 |
Why?
| | Thoracoscopy | 1 | 2020 | 60 | 0.040 |
Why?
| | Liver | 2 | 2006 | 1864 | 0.040 |
Why?
| | Image-Guided Biopsy | 1 | 2019 | 41 | 0.040 |
Why?
| | Medical Oncology | 1 | 2022 | 345 | 0.040 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2020 | 76 | 0.040 |
Why?
| | Societies, Medical | 1 | 2024 | 907 | 0.040 |
Why?
| | Perioperative Period | 1 | 2017 | 69 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2004 | 1369 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2025 | 3416 | 0.030 |
Why?
| | Occipital Bone | 1 | 2017 | 18 | 0.030 |
Why?
| | Parotid Gland | 1 | 2017 | 17 | 0.030 |
Why?
| | Gastric Emptying | 1 | 2017 | 36 | 0.030 |
Why?
| | Carcinoma, Lobular | 1 | 2017 | 59 | 0.030 |
Why?
| | Health Behavior | 1 | 2002 | 802 | 0.030 |
Why?
| | Neck | 1 | 2017 | 107 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2024 | 3017 | 0.030 |
Why?
| | Sex Factors | 1 | 2022 | 2107 | 0.030 |
Why?
| | Raffinose | 2 | 2006 | 29 | 0.030 |
Why?
| | Consensus | 1 | 2017 | 467 | 0.030 |
Why?
| | Allopurinol | 2 | 2006 | 70 | 0.030 |
Why?
| | Perioperative Care | 1 | 2018 | 235 | 0.030 |
Why?
| | Glucose | 1 | 2020 | 1053 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 790 | 0.020 |
Why?
| | Adenosine | 2 | 2006 | 256 | 0.020 |
Why?
| | Glutathione | 2 | 2006 | 369 | 0.020 |
Why?
| | Glasgow Coma Scale | 1 | 2014 | 211 | 0.020 |
Why?
| | Vital Signs | 1 | 2012 | 39 | 0.020 |
Why?
| | Radiation Injuries | 1 | 2014 | 149 | 0.020 |
Why?
| | New South Wales | 1 | 2012 | 23 | 0.020 |
Why?
| | Incidence | 1 | 2019 | 2936 | 0.020 |
Why?
| | Baltimore | 1 | 2012 | 71 | 0.020 |
Why?
| | Italy | 1 | 2012 | 118 | 0.020 |
Why?
| | Child | 6 | 2014 | 22693 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2025 | 3926 | 0.020 |
Why?
| | Disease Progression | 1 | 2020 | 2867 | 0.020 |
Why?
| | Pharmaceutical Preparations | 1 | 2013 | 172 | 0.020 |
Why?
| | Hospital Costs | 1 | 2012 | 131 | 0.020 |
Why?
| | Biological Therapy | 1 | 2011 | 30 | 0.020 |
Why?
| | Child, Preschool | 4 | 2014 | 11913 | 0.020 |
Why?
| | Albuminuria | 1 | 1992 | 190 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2012 | 517 | 0.020 |
Why?
| | Injury Severity Score | 1 | 2012 | 572 | 0.020 |
Why?
| | Lung | 1 | 2023 | 4122 | 0.020 |
Why?
| | Glomerular Filtration Rate | 1 | 2013 | 745 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 6073 | 0.020 |
Why?
| | Immunosuppressive Agents | 1 | 2013 | 829 | 0.020 |
Why?
| | Carcinoembryonic Antigen | 1 | 2008 | 40 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2014 | 6460 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2008 | 108 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1998 | 0.020 |
Why?
| | Radiopharmaceuticals | 1 | 2008 | 210 | 0.020 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2008 | 164 | 0.020 |
Why?
| | Retreatment | 1 | 2007 | 79 | 0.020 |
Why?
| | Infant | 3 | 2014 | 10114 | 0.020 |
Why?
| | Colorado | 1 | 2017 | 4595 | 0.020 |
Why?
| | Cholecystectomy | 1 | 2007 | 63 | 0.020 |
Why?
| | Incidental Findings | 1 | 2007 | 81 | 0.020 |
Why?
| | Positron-Emission Tomography | 1 | 2008 | 343 | 0.020 |
Why?
| | Neoplasm, Residual | 1 | 2007 | 143 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2007 | 183 | 0.020 |
Why?
| | Tablets, Enteric-Coated | 1 | 2006 | 5 | 0.010 |
Why?
| | Hepatitis B | 1 | 2007 | 66 | 0.010 |
Why?
| | Histidine | 1 | 2006 | 67 | 0.010 |
Why?
| | Radiography | 1 | 2008 | 861 | 0.010 |
Why?
| | Psychological Tests | 1 | 1986 | 127 | 0.010 |
Why?
| | Graft Rejection | 1 | 2009 | 516 | 0.010 |
Why?
| | Overweight | 1 | 2010 | 614 | 0.010 |
Why?
| | Tryptophan | 1 | 2006 | 184 | 0.010 |
Why?
| | Glutathione Disulfide | 1 | 2004 | 30 | 0.010 |
Why?
| | Hepatitis C | 1 | 2007 | 251 | 0.010 |
Why?
| | Insulin | 2 | 2006 | 2525 | 0.010 |
Why?
| | Sulfamethoxypyridazine | 1 | 1983 | 1 | 0.010 |
Why?
| | Trimethoprim | 1 | 1983 | 7 | 0.010 |
Why?
| | Liver Function Tests | 1 | 2004 | 103 | 0.010 |
Why?
| | Gastrointestinal Diseases | 1 | 2006 | 220 | 0.010 |
Why?
| | Anti-Infective Agents, Urinary | 1 | 1983 | 16 | 0.010 |
Why?
| | Amphotericin B | 1 | 2003 | 36 | 0.010 |
Why?
| | Liver Diseases | 1 | 2006 | 304 | 0.010 |
Why?
| | Antifungal Agents | 1 | 2003 | 153 | 0.010 |
Why?
| | Immunocompromised Host | 1 | 2003 | 201 | 0.010 |
Why?
| | Cause of Death | 1 | 2004 | 456 | 0.010 |
Why?
| | Reperfusion Injury | 1 | 2004 | 300 | 0.010 |
Why?
| | Urinary Tract Infections | 1 | 1983 | 209 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 1992 | 2219 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 1992 | 3930 | 0.010 |
Why?
| | Cholesterol | 1 | 1992 | 411 | 0.000 |
Why?
| | Blood Pressure | 1 | 1992 | 1765 | 0.000 |
Why?
| | Sulfamethoxazole | 1 | 1983 | 7 | 0.000 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1983 | 43 | 0.000 |
Why?
| | Escherichia coli Infections | 1 | 1983 | 125 | 0.000 |
Why?
| | Drug Combinations | 1 | 1983 | 400 | 0.000 |
Why?
| | Microbial Sensitivity Tests | 1 | 1983 | 367 | 0.000 |
Why?
| | Escherichia coli | 1 | 1983 | 832 | 0.000 |
Why?
| | Clinical Trials as Topic | 1 | 1983 | 1064 | 0.000 |
Why?
|
|
Gleisner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|